



# International Regulatory Endeavor towards Sound Development of Human Cell Therapy Products

February 18-19th, 2015  
Hitotsubashi Hall, Tokyo, Japan

Organized by  
International Alliance for Biological Standardization (IABS)

With the support from  
Pharmaceuticals and Medical Devices Agency (PMDA)  
Japan Science and Technology Agency (JST)  
National Institute of Biomedical Innovation (NIBIO)

\*\*\*  
World Health Organization (WHO)

Under the auspices of  
Ministry of Health, Labour and Welfare (MHLW): Pending (申請中)  
Forum for Innovative Regenerative Medicine (FIRM)  
Japan Pharmaceutical Manufacturers Association (JPMA)  
The Japanese Society for Regenerative Medicine (JSRM)

## Registration fees

Early registration (before January 31, 2015)	
<b>Government / Trainee / Student</b>	
IABS member	US\$ 80
Non-IABS member	US\$ 90
<b>Academia / Research Institute</b>	
IABS member	US\$ 250
Non-IABS member	US\$ 300
<b>Industry</b>	
IABS member	US\$ 400
Non-IABS member	US\$ 500
Regular registration (February 1 - February 19, 2015)	
<b>Government / Trainee / Student</b>	
IABS member	US\$ 120
Non-IABS member	US\$ 140
<b>Academia / Research Institute</b>	
IABS member	US\$ 300
Non-IABS member	US\$ 350
<b>Industry</b>	
IABS member	US\$ 500
Non-IABS member	US\$ 550

## Secretariat

Hitomi, MURAOKA  
Division of Cell-Based Therapeutic Products  
National Institute of Health Sciences (NIHS)  
1-18-1, Kamiyoga, Setagaya-ku, Tokyo 158-8501, JAPAN  
Telephone/Facsimile : +81-3-5717-3831 E-mail : muraoka@nihs.go.jp

## AGENDA (Draft 5 JAN. 2015)

### Day 1 – Wednesday, FEBRUARY 18, 2015

#### Session 1 Keynote Lecture

Session 2 Introduction of the meeting including the concept of a minimum consensus package plus case by case approaches for evaluating human cell therapy products (hCTPs)

Session 3 Specific points to consider for the evaluation and control of hCTPs that are different from those of traditional biological/biotechnological protein products (1)

### Day 2 – Thursday, FEBRUARY 19, 2015

Session 4 Specific points to consider for the evaluation and control of hCTPs that are different from those of traditional biological/biotechnological protein products (2)

Session 5 Identification of specific points/issues for specific types of products, as well as very critical points/issues for various types of products (1)

Session 6 Identification of specific points/issues for specific types of products, as well as very critical points/issues for various types of products (2)

Please visit the workshop website: <http://www.iabs.org/>  
<http://iabs-tokyo-2015.jimdo.com/>

PMDA IABS

